EyePoint (EYPT) Q3 2026 earnings review
EyePoint halts its lead eye program and cuts half its staff
EyePoint, a drug developer for serious eye diseases, abandoned its lead program after two late-stage trials missed their main goal. Both studies of DURAVYU in age-related vision loss failed to match the vision gains of standard eye injections, prompting chief executive Jay S. Duker to pivot the business to diabetic eye disease. Trial bills pushed the third-quarter net loss to $96 million and cut cash to $118 million.
| Cash and marketable securities | $118M $180M last quarter |
|---|---|
| Research and development spend | $81.7M +71% from a year ago |
| Workforce reduction | 53% to save about $30M a year |
| Cash runway outlook | Cut into late Q3 2027 vs into Q4 2027 previously |
⚖️ Verdict: 🔴🔴 Very Bearish
The story got worse because the company lost its nearest path to market and its cash outlook no longer reaches the next major trial readout. Cutting half the staff will save about $30 million a year, but the updated plan only funds the business into late third quarter of 2027, just before diabetic eye results arrive in early fourth quarter. One bright spot: repeat dosing across more than 900 patients showed no serious insert safety issues.
The question now is whether DURAVYU's extra anti-inflammatory action can pass the same vision test in diabetic eye disease that it just failed in age-related macular degeneration. Supporters point to stronger mid-stage diabetic results, while skeptics see identical six-month dosing risks and a looming cash shortfall. The late-stage COMO and CAPRI readouts in early fourth quarter of 2027 will settle it.
🐂 Bull Case
Diabetic Eye Trials Enrolled Faster Than Planned
With its first eye program stopped, EyePoint now relies on DURAVYU, its slow-release eye insert, in diabetic macular edema (DME), a diabetes-related swelling of the retina. The company runs two identical late-stage trials, COMO and CAPRI, testing the insert every six months against standard aflibercept eye injections.
Doctors enrolled over 550 patients across both trials in five months, finishing on July 30 and beating the earlier 480-patient goal. That speed matters because it locks in a clear timeline for the company's remaining shots on goal. EyePoint expects main results "early in the fourth quarter of 2027".
What to watch: patient retention and masked discontinuation rates in COMO and CAPRI over the next three quarters. Keeping dropouts near the 5% rate seen in the earlier trials would protect the statistical power of the readout.
Repeat Dosing Cleared Major Eye Safety Hurdles
Doctors and analysts had questioned whether putting new drug inserts into the eye every six months would cause cloudiness, floating particles, or severe inflammation. Because existing eye injections are very safe, any serious physical side effect from the insert could sink the entire drug platform.
Across both late-stage trials in over 900 randomized patients, repeat dosing of DURAVYU showed no insert migration, no front-of-eye cloudiness, no free-floating drug particles, and no retinal blood vessel inflammation. EyePoint will keep some patients in the second year of those studies to finish building the safety database required for a futurediabetic eye disease filing.
What to watch: detailed adverse event tables at upcoming medical meetings, specifically rates of cataracts and mild eye floaters. Clean numbers across the full patient group would confirm that the physical insert is safe enough for routine use.
🐻 Bear Case
Two Trial Misses End Lead Eye Program
"The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56," chief executive Jay S. Duker said. Wet age-related macular degeneration (wet AMD) is a leading cause of blindness in older adults, and EyePoint had aimed to make DURAVYU the first long-acting tyrosine kinase inhibitor — a small-molecule drug that blocks blood-vessel growth receptors — approved for it.
Despite Duker's focus on fluid control, both the LUGANO trial in August and the LUCIA trial in October "did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept control". Best-corrected visual acuity (BCVA) measures how many letters a patient can read on an eye chart, which is the standard required by US regulators.
- LUGANO treatment burden: reduced by 42% vs control, with 54% of eyes needing no extra injections through Week 56
- LUCIA treatment burden: reduced by 38% vs control, with 52% of eyes needing no extra injections through Week 56
- Program outcome: EyePoint will "conclude the wet AMD program before completion of the full second year of the Phase 3 studies"
Fewer rescue injections did not save the program because vision scores across the full trial population trailed the standard treatment by too much. Because both trials use the same six-month insert and the same statistical test as the ongoing diabetic eye studies, the failure raises the bar for proving that DURAVYU's extra anti-inflammatory mechanism can deliver matching vision gains next year.
What to watch: the exact letter-score gap between DURAVYU and aflibercept when full LUCIA data is presented. A wide gap among patients who needed rescue shots would show where the six-month dosing schedule wore off.
Cash Runway Falls Short of Next Readout
"Capital discipline is now one of our highest priorities," finance chief George O. Elston said, noting that EyePoint wants to preserve the funds needed to reach its diabetic eye disease readout. Running four concurrent late-stage trials pushed third-quarter research and development spending up 71% from a year ago to $81.7 million.
By our math, cash and marketable securities fell by $62.3 million during the quarter to $118.2 million. Even after raising $10 million from stock sales after the quarter closed and cutting over half the staff, EyePoint now expects its money to "fund operations into late third quarter of 2027". That stops just short of the COMO and CAPRI results due "early in the fourth quarter of 2027".
What to watch: quarterly cash burn in the first half of 2027 and any new licensing or share-sale announcements. EyePoint must bridge at least one quarter of funding before investors see the diabetic eye trial results.
Factory and Sales Buildout Lose Near-Term Purpose
Over the past year, EyePoint built out a commercial sales team and staffed a 41,000-square-foot manufacturing plant in Northbridge, Massachusetts to prepare for a 2026 regulatory filing in wet AMD. General and administrative costs — which cover executive pay, commercial planning, and overhead — rose 6.3% from a year ago to $15.4 million in the third quarter.
Stopping the wet AMD trials leaves that commercial infrastructure with no product to launch for at least another year and a half. While the Northbridge plant will still supply the diabetic eye program, the company spent heavily to prepare for a pre-approval inspection that is now delayed.
What to watch: general and administrative expense in the first quarter of 2027, the first full period after the layoffs. A sharp drop is needed to show that commercial overhead has been paused.
👓 Other Themes
EyePoint Cuts Half Its Staff to Save Cash
Following the second trial failure in October, EyePoint's board approved a restructuring plan to focus solely on diabetic macular edema. The biopharmaceutical company is cutting about 53% of its workforce and Winding down most of the wet AMD studies early, which it estimates will save about $30 million a year. The release did not disclose the one-time severance charges for the layoffs.
💲 Other KPIs
Share count rose 27.2% from a year ago and 3.1% from last quarter. The increase came from last October's public stock offering and ongoing sales under an at-the-market equity program, which raised another $10 million after the third quarter ended and spreads future drug upside across more shares.
Down 65.9% from $20.1 million at the end of 2025, though up slightly from $6.4 million last quarter. Prepaid expenses are upfront payments to clinical trial contractors; their drop shows that advance deposits for the late-stage eye trials have largely been worked through as the studies progressed.
Fell 21.7% from $0.97 million a year ago, after dropping more than 90% in the first two quarters of the year when upfront accounting revenue from an older eye drug license ended. Small product sales of $0.53 million and royalties of $0.18 million provide almost no offset to research costs.
🔮 Guidance
Cut. Management now expects its $118 million in cash, plus $10 million raised after quarter-end and $30 million in yearly cost cuts, to last into late third quarter of 2027. For the previous four quarters, the US drug developer had stated its cash would reach into the fourth quarter of 2027. By our math, without the planned spending cuts, third-quarter burn of $62 million would exhaust the balance in two quarters.
Unchanged. EyePoint narrowed the expected timing for main results from both diabetic macular edema trials to early in the fourth quarter of 2027, consistent with its prior fourth-quarter target. Because both trials finished enrolling over 550 patients on July 30, 2026 and test vision after one year of treatment, the readout date is now anchored to the trial calendar.
❓ Key Questions
How wide was the vision gap in LUGANO and LUCIA?
EyePoint said DURAVYU matched standard treatment in the half of patients who needed no extra injections, which means it trailed in the half who did. Investors need the exact letter-score miss in the full group to judge the risk to the diabetic eye trials.
How will EyePoint bridge the funding gap to Q4 2027?
The updated cash outlook runs out in late third quarter of 2027, just weeks before the pivotal diabetic eye data arrives in early fourth quarter. Management needs to clarify how much more cash is required to get comfortably past the readout.
What are the cash severance costs for the 53% layoff?
Cutting more than half the workforce will save an estimated $30 million a year, but the release did not state the upfront cash severance bill or when the full quarterly savings will take effect in 2027.
How much will winding down wet AMD cut quarterly R&D?
Research spending hit $81.7 million in the third quarter across four late-stage trials. Because some wet AMD patients will stay on through year two for safety tracking, investors need to know how fast trial bills will actually fall.